Agenus Inc.
AGENHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAgenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. The company carries a $285.9M market cap, placing it firmly in the micro-cap category. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Market Cap
$285.9M
Beta
1.32
P/E (TTM)
2.50
P/E (Fwd)
-57.55
EPS (TTM)
$2.53
EPS (Fwd)
$-0.11
ROE
—
ROA
12.5%
Cash
$18.7M
Total Debt
$40.7M
Free CF
-$74.8M
52W Change
52.5%
Annual Financials
Cash vs Debt
Where AGEN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AGEN finished 16.17% above its 150-day moving average ($5.32) and 28.48% above its 200-day moving average ($4.81). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AGEN overbought or oversold?
At the October 20, 2026 close, AGEN's RSI(14) was 17.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Agenus Inc. carries $40.7M in total debt against $18.7M in cash reserves — debt is roughly 2.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$74.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on assets of 12.5% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $98.0M to $114.2M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing AGEN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.